Analogously, in a xenogeneic ovarian carcinoma model, it has been demonstrated that the chemotherapeutic drug gemcitabine increased the expression of NKG2D ligands and death receptors on tumor cells, and the adoptive transfer of NK cells in combination with gemcitabine additively decreased ovarian cancer growth (145). The gene discussed is KLRK1; the disease is ovarian carcinoma.